Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Shenzhen Chipscreen Biosciences Co. Ltd. is currently addressing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct art units and examiners, indicating a broad technical range for the pending applications.
ABDALHAMEED, MANAHIL MIRGHANI ALI is the busiest examiner, handling 1 pending office action. Because each action is assigned to a different examiner and art unit, the company is managing separate review processes without overlap in personnel.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279219 | BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | MOORE, SUSANNA | 5d overdue |
| 18556100 | PHARMACEUTICAL COMPOSITION CONTAINING JAK3/JAK1/TBK1 SELECTIVE INHIBITOR AND MEDICAL USE THEREOF | ABDALHAMEED, MANAHIL MIRGHANI ALI | 28d |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556100 | PHARMACEUTICAL COMPOSITION CONTAINING JAK3/JAK1/TBK1 SELECTIVE INHIBITOR AND MEDICAL USE THEREOF | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | Other | Final Rejection | 28d | Pending | Oct 19, 2023 |
| 18279219 | BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | MOORE, SUSANNA | 1624 | §102DP | Final Rejection | 5d overdue | Pending | Aug 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenzhen Chipscreen Biosciences Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Manahil Mirghani Ali Abdalhameed has the most, with 1 of Shenzhen Chipscreen Biosciences Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
